Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cytrx Corp (OP: CYTR ) N/A UNCHANGED Last Price Updated: 1:53 PM EDT, Oct 5, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cytrx Corp < Previous 1 2 Next > LadRx Corporation Announces OTCQB Ticker Change to LADX October 05, 2022 From LadRx Corporation Via Business Wire CytRx Corporation Relaunches as LadRx Corporation September 23, 2022 From CytRx Corporation Via Business Wire European Patent Office Awards CytRx Key Patent September 07, 2022 From CytRx Corporation Via Business Wire CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors August 09, 2022 From CytRx Corporation Via Business Wire CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock May 19, 2022 From CYTRX CORPORATION Via Business Wire CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc. May 17, 2022 From CytRx Corporation Via Business Wire CytRx Partners with Oncology Development Expert to Advance LADR Platform April 20, 2022 From CytRx Corporation Via Business Wire CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress March 21, 2022 From CytRx Corporation Via Business Wire Orphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce March 11, 2022 Orphazyme A/S's (NASDAQ: ORPH) board of directors has called for a court-mediated restructuring, prompting the second round of layoffs in less than a year. The in-... Via Benzinga CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C February 24, 2022 From CytRx Corporation Via Business Wire CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C February 14, 2022 From CytRx Corporation Via Business Wire CytRx to Hold Town Hall for Stockholders on Thursday, January 20th January 18, 2022 From CytRx Corporation Via Business Wire CytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference January 07, 2022 From CytRx Corporation Via Business Wire CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer January 03, 2022 From CytRx Corporation Via Business Wire CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer December 21, 2021 From CytRx Corporation Via Business Wire CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada November 30, 2021 From CytRx Corporation Via Business Wire CytRx Comments on Quarterly Results and Recent Strategic Initiatives November 12, 2021 From CytRx Corporation Via Business Wire CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada November 09, 2021 From CytRx Corporation Via Business Wire CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C November 02, 2021 From CytRx Corporation Via Business Wire CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment October 14, 2021 From CytRx Corporation Via Business Wire CytRx to Present at Upcoming Virtual LD Micro Conference October 05, 2021 From CytRx Corporation Via Business Wire CytRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 08, 2021 From CytRx Corporation Via Business Wire CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C August 24, 2021 From CytRx Corporation Via Business Wire CytRx Comments on Quarterly Results and Recent Strategic Initiatives August 12, 2021 From CytRx Corporation Via Business Wire CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders July 29, 2021 From CytRx Corporation Via Business Wire CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022 July 29, 2021 From CytRx Corporation Via Business Wire These OTC Securities Had the Most Trading Activity in June July 20, 2021 Photo by Cris Ovalle on Unsplash OTC Markets trading volume was still led by cryptocurrencies and cannabis for the month of June, but many other securities shined comparatively as... Via Benzinga Topics Cannabis Exposures Cannabis CytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional Investor July 16, 2021 From CytRx Corporation Via Business Wire CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor July 13, 2021 From CytRx Corporation Via Business Wire CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C June 30, 2021 From CytRx Corporation Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.